Lilly pres Deirdre Connelly defects to GSK

Share this article:
Deirdre Connelly
Deirdre Connelly

In joint company statements today, GlaxoSmithKline and Lilly announced that Deirdre Connelly has resigned as president of US operations at Lilly, to become president, North American pharmaceuticals, at GlaxoSmithKline. Connelly will begin her new role at GSK on February 9, 2009.

In the statement, GSK CEO Andrew Witty said Connelly is “somebody who truly understands the needs of patients and our customers and can drive the efforts we are making to reshape this business and improve future growth.” Connelly had led Lilly's US operations since 2005.

Lilly, in turn, promoted Enrique Conterno, currently senior vice president of healthcare professional markets, to president, effective immediately. Conterno will report to Bryce Carmine, EVP of global marketing and sales.

Conterno “understands the complexities of the US marketplace, he has stressed the need to accelerate the transformation that is under way at this company, and he is focused on the needs of the patients we serve,” said John Lechleiter, Lilly's chairman, president and CEO, in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...